A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
Clinical trial NCT07330440 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07330440
- Sponsor
- Changchun BCHT Biotechnology Co.
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-13
- Primary completion
- 2027-03-04
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.